Superpower Pricing Analysis & Total Cost: Is It Worth It?

What Is Superpower and How Does Its Business Model Work?

Superpower operates as a subscription-based concierge telehealth service. The core pitch: pay one annual fee, get a clinician-ordered lab panel twice a year, review results with a physician, and receive prescriptions for GLP-1 agonists, peptides, or hormone therapies if clinically appropriate.

The model differs from fee-for-service telehealth (like Teladoc or Amazon Clinic) and from single-medication platforms (like Ro or Hims). Superpower positions itself closer to companies like Function Health or Parsley Health, but with a heavier emphasis on optimization prescriptions rather than purely diagnostic surveillance.

The Subscription vs. Medication Split

This distinction matters for cost analysis. The membership fee covers access, consultations, and labs. It does not cover medications. A patient who joins at $299 per year and receives no prescriptions has spent $299. A patient prescribed compounded tirzepatide at $400 per month has spent roughly $5,100 per year all-in.

Understanding this split prevents sticker-shock after sign-up. Lab-only or consult-only users get a very different value proposition than heavy medication users.

What the Labs Actually Cover

Reported panel contents include a complete metabolic panel, CBC with differential, HbA1c, fasting insulin, lipid panel, thyroid-stimulating hormone, free T3, free T4, sex hormone binding globulin, total and free testosterone, estradiol, DHEA-S, IGF-1, C-reactive protein (high-sensitivity), homocysteine, ferritin, and vitamin D. This is a clinically meaningful panel. For context, Quest Diagnostics charges $189 to $400 for a comparably comprehensive panel ordered a la carte. Getting two per year included in a $299 membership changes the math considerably.

Superpower Pricing: Tier Breakdown and What You Actually Pay

The table below maps the reported cost layers a Superpower patient moves through, from sign-up to fully medicated. These figures are based on publicly available information and patient-reported data as of early 2025. HealthRX does not have a financial relationship with Superpower.

| Cost Layer | Reported Range | Notes | |---|---|---| | Annual membership | $299/year | Covers labs + consults | | Compounded semaglutide | $150-$350/month | Dose-dependent; pharmacy varies | | Compounded tirzepatide | $300-$450/month | Higher demand = higher price | | Brand-name Wegovy (semaglutide 2.4 mg) | $1,349/month list price | Insurance may reduce cost significantly | | Peptide protocols (e.g., BPC-157) | $80-$200/month | Self-injected; kit typically shipped | | TRT (testosterone cypionate) | $50-$150/month | If clinically indicated |

Why Compounded GLP-1 Prices Vary So Much

Compounded semaglutide pricing is not set by the brand. Each 503A or 503B compounding pharmacy sets its own price, and Superpower (like most telehealth platforms) partners with a network of compounders. Prices vary by dose (0.25 mg starter vs. 2.4 mg maintenance), by vial size (4-week vs. 12-week supply), and by state regulations.

The FDA placed semaglutide on its drug shortage list in 2022 and updated that designation through 2024, which legally permitted compounding [1]. The shortage status for semaglutide injection (Ozempic/Wegovy) has been subject to ongoing FDA review, and compounders must comply with current shortage designations before dispensing [2]. Patients should confirm current compounding legality with their prescriber at the time of signing up.

Tirzepatide Compounding: A Different Regulatory Picture

Tirzepatide (the active ingredient in Mounjaro and Zepbound) was placed on the FDA shortage list, permitting 503A and 503B compounders to produce it. As of early 2025, the FDA has taken enforcement actions against some compounders producing tirzepatide after indicating shortage resolution [3]. Superpower prescribers operating correctly should be communicating these changes to patients in real time. If a platform is still prescribing compounded tirzepatide without addressing the current regulatory environment, that is a yellow flag worth asking about directly.

Is Superpower Legit? Regulatory and Clinical Credibility Assessment

Legitimacy in telehealth has two dimensions: legal compliance and clinical quality. These are related but not identical.

Legal Compliance

Superpower uses licensed physicians and nurse practitioners operating under state medical board rules and the Ryan Haight Act for controlled substances. Peptides like BPC-157 occupy a complicated regulatory space. BPC-157 is not FDA-approved and is classified as a research chemical in some contexts, yet compounding pharmacies have dispensed it clinically for years. The FDA has issued warning letters to compounders of certain peptides [4]. Patients should ask explicitly whether any prescribed peptide is sourced from an FDA-registered facility.

GLP-1 prescriptions, by contrast, follow well-established telehealth prescription pathways. Semaglutide 2.4 mg (Wegovy) is FDA-approved for chronic weight management in adults with a BMI of 30 or above, or BMI <27 with at least one weight-related comorbidity [5].

Clinical Quality Signals

Quality telehealth prescribing means: (1) reviewing lab results before prescribing, (2) monitoring for side effects, (3) adjusting doses based on response, and (4) escalating to in-person care when indicated. Superpower's model, which includes twice-yearly labs and physician review, supports at least points 1 and 2 if used consistently.

The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean body weight reduction at 68 weeks vs. 2.4% with placebo (P<0.001), with nausea reported in 44% of the active group [6]. A telehealth prescriber who does not counsel patients on this expected adverse effect profile or who does not adjust dosing during the ramp-up phase is not meeting the standard of care documented in that trial protocol. Asking Superpower's clinical team directly how they handle dose titration is a reasonable due-diligence step.

What Superpower Prescribes: GLP-1, Peptides, and Hormones

GLP-1 Agonists

Semaglutide and tirzepatide are the two GLP-1 related medications most reported by Superpower users. Semaglutide (as Ozempic or Wegovy) carries FDA approval for type 2 diabetes and chronic weight management, respectively. Tirzepatide (as Mounjaro or Zepbound) is FDA-approved for both indications as well [7].

The SURMOUNT-1 trial (N=2,539) found tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks vs. 3.1% with placebo [8]. That trial enrolled adults with BMI of 30 or above, or BMI <27 with a comorbidity, without type 2 diabetes. These are the populations for whom a Superpower prescription would be most directly evidence-supported.

Peptides: What the Evidence Actually Supports

BPC-157 (body protection compound 157) has shown tissue-protective effects in rodent models, including gastric mucosal healing and tendon repair [9]. Human randomized controlled trial data is largely absent. A 2018 systematic review found no completed phase II or III human trials for BPC-157 [10]. Prescribing this peptide is legal in some states but sits outside the normal evidence hierarchy that governs FDA-approved medications.

CJC-1295 (a growth hormone-releasing hormone analog) and ipamorelin (a growth hormone secretagogue) are often prescribed together to increase endogenous growth hormone pulses. IGF-1 data from these combinations in healthy adults show modest, short-term GH elevation, but no long-term outcomes trials exist for anti-aging or body composition endpoints specifically.

PT-141 (bremelanotide) is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women [11]. Compounded versions differ in formulation but share the same mechanism. This is one of the better-supported peptide options on Superpower's reported formulary.

TB-500 (thymosin beta-4 fragment) has even thinner human data than BPC-157. Animal models suggest wound-healing properties, but there is no clinical trial infrastructure supporting its routine prescription.

Patients considering peptide protocols through Superpower should ask the prescribing physician: what specific endpoint are we targeting, how will we measure it, and what is the stopping criterion if we see no response?

Hormone Therapies

Testosterone replacement therapy for men with documented hypogonadism (total testosterone <300 ng/dL per the American Urological Association guideline threshold) is well-supported [12]. Superpower's twice-yearly testosterone panel allows for reasonable monitoring of hematocrit, PSA, and testosterone levels. The Endocrine Society's 2018 guideline specifies that testosterone therapy should be initiated only after two morning fasting blood draws confirm low levels [13], a bar that Superpower's lab model can meet if the prescriber follows protocol.

For women, estradiol and progesterone prescribing should follow NAMS (North American Menopause Society) guidance, which supports hormone therapy for menopausal symptoms in women under 60 or within 10 years of menopause onset without contraindications [14].

Superpower vs. Alternatives: A Direct Cost and Coverage Comparison

Superpower vs. Function Health

Function Health (co-founded by Dr. Mark Hyman) focuses almost entirely on diagnostics: 100+ biomarker panels twice a year for $499 per year. Function does not prescribe medications. Superpower charges less for labs but includes prescribing access. If you want labs only, Function Health's panel is broader. If you want labs plus prescriptions, Superpower's all-in model may be more cost-efficient.

Superpower vs. Hims/Hers

Hims and Hers offer compounded semaglutide starting around $199 per month without a separate membership fee. That model works for patients who only want a GLP-1 and do not need a broad lab panel or peptide access. For a straightforward semaglutide prescription, Hims/Hers may cost less over 12 months than Superpower ($2,388 vs. $2,099-$4,499 all-in). However, Hims/Hers does not currently offer peptide protocols or testosterone therapy within the same account.

Superpower vs. Marek Health

Marek Health is a direct competitor in the optimization concierge space, offering lab-plus-hormone-plus-peptide protocols with coaching. Marek's pricing is less publicly listed than Superpower's but is generally reported in a similar annual range. Clinical depth varies by assigned provider on both platforms.

Superpower vs. Doing It Yourself

A patient who orders their own labs through Ulta Lab Tests or LabCorp OnDemand, books a single telemedicine visit through Sesame for $75, and obtains a GLP-1 prescription through a discount GLP-1 telehealth service (e.g., Push Health) could potentially replicate the functional core of Superpower's offering for less annually. The trade-off is coordination burden: managing multiple vendors, synthesizing results without a dedicated physician, and navigating medication titration alone.

Superpower Reviews: What Patients and Clinicians Report

Patient reviews on third-party sites (Reddit r/Peptides, Trustpilot, and Google) show a bimodal pattern common to premium telehealth services. Positive reviews emphasize convenience, comprehensive labs, and access to prescriptions that primary care physicians declined to write. Negative reviews cluster around two themes: slow response times from clinical staff and confusion about medication cost after sign-up.

The confusion about cost is addressable before you join. The membership fee is not the total cost. Ask specifically: what will my medications cost per month, who is the compounding pharmacy, and what is the titration schedule?

One Reddit user in r/Peptides (January 2025) wrote that their all-in cost for Superpower membership plus compounded semaglutide was "about $230/month when averaged over the year, which beats what I was paying at my old weight loss clinic." That figure is consistent with the lower end of the cost range HealthRX calculated above.

The absence of peer-reviewed outcome data specific to Superpower's patient cohort means there is no published evidence that Superpower members achieve better clinical results than patients managed through standard telehealth channels. This gap is common across all concierge optimization platforms and should not be interpreted as evidence of ineffectiveness, but it does mean any comparative claims from the brand itself should be read skeptically.

How to Evaluate Whether Superpower Is Worth It for You

The math depends on four variables: which medications you will be prescribed, how long you stay on them, what you would otherwise pay for equivalent lab work, and how much you value coordinated care under one physician relationship.

Run this simple calculation before signing up:

1. Get a quote from Quest or Labcorp for the specific panels you need twice yearly. Subtract the total from $299. If the difference is negative, the lab value alone does not justify the membership.
2. Price the same GLP-1 prescription through a competing telehealth platform (Hims, Ro, Found, Calibrate). If Superpower's compounding pharmacy charges more, ask why before committing.
3. If you want peptides not available elsewhere, assign a personal value to that access. No competitor comparison exists because the peptide telehealth market is fragmented.
4. If you want one physician who knows your full panel history across hormones, metabolic markers, and peptide protocols, that coordination has real value that is difficult to price.

Superpower makes the most financial sense for patients who will use two or more of its prescription categories simultaneously (e.g., semaglutide plus testosterone plus one peptide) and who want a single physician to manage the interactions. For a patient who only wants a GLP-1, cheaper single-purpose platforms likely win on price.